{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:56:51Z","timestamp":1785466611136,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Heart Association of Thailand"},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The advantage of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) in patients with preserved LV systolic function is uncertain. We aimed to investigate the effects of ACEI\/ARB in high atherosclerotic risk patients without overt heart failure (HF) on long-term major cardiovascular outcomes (MACEs). The Cohort Of patients with high Risk for cardiovascular Events (CORE-Thailand) registry is a prospective, multicenter, observational, longitudinal study of Thai patients with high atherosclerotic risk. The patients with ejection fraction\u2009&lt;\u200950% were excluded. Among 8513 recruited patients, there were 4246 patients included into final analysis after propensity score matching. At 5-years follow-up, Cox regression analysis showed that ACEI\/ARB was significantly associated with reduced risk of all-cause mortality or non-fatal myocardial infarction, non-fatal stroke and HF hospitalization (HR 0.82, 95% CI 0.70\u20130.96, <jats:italic>P<\/jats:italic>\u2009=\u20090.011). The benefit was driven by the reduced all-cause mortality and HF. Subgroup analysis demonstrated that ACEI\/ARB decreased risk of long-term MACEs in patients with diabetes (HR 0.77, 95% CI 0.63\u20130.94, <jats:italic>P<\/jats:italic>\u2009=\u20090.011) and patients not taking statin (HR 0.57, 95% CI 0.40\u20130.82, <jats:italic>P<\/jats:italic>\u2009=\u20090.002). We demonstrated that the use of ACEI\/ARB was associated with reduced risk of long-term MACEs in a large cohort of high atherosclerotic risk patients. Reduction of all-cause mortality and HF were likely the main contributors to the benefit of ACEI\/ARB.<\/jats:p>","DOI":"10.1038\/s41598-023-50430-8","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T14:02:29Z","timestamp":1703772149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of renin angiotensin system inhibitors on long-term major cardiovascular outcomes in patients with high atherosclerotic cardiovascular risk"],"prefix":"10.1038","volume":"13","author":[{"given":"Wanwarang","family":"Wongcharoen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichanan","family":"Osataphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriluck","family":"Gunaparn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suphot","family":"Srimahachota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornwalee","family":"Porapakkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchai","family":"Dutsadeevettakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arintaya","family":"Phrommintikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"50430_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368 (2021).","journal-title":"Eur. Heart J."},{"key":"50430_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/ajh\/hpac018","volume":"35","author":"BI Levy","year":"2022","unstructured":"Levy, B. I. & Mourad, J. J. Corrigendum to: Renin angiotensin blockers and cardiac protection: From basics to clinical trials. Am. J. Hypertens. 35, 676. https:\/\/doi.org\/10.1093\/ajh\/hpac018 (2022).","journal-title":"Am. J. Hypertens."},{"key":"50430_CR3","first-page":"937","volume":"3","author":"RA Hammoud","year":"2007","unstructured":"Hammoud, R. A., Vaccari, C. S., Nagamia, S. H. & Khan, B. V. Regulation of the renin-angiotensin system in coronary atherosclerosis: A review of the literature. Vasc. Health Risk Manag. 3, 937\u2013945 (2007).","journal-title":"Vasc. Health Risk Manag."},{"key":"50430_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","volume":"50","author":"M Bader","year":"2010","unstructured":"Bader, M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu. Rev. Pharmacol. Toxicol. 50, 439\u2013465. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105610 (2010).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"50430_CR5","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1161\/01.CIR.0000124061.78478.94","volume":"109","author":"R Candido","year":"2004","unstructured":"Candido, R. et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109, 1536\u20131542. https:\/\/doi.org\/10.1161\/01.CIR.0000124061.78478.94 (2004).","journal-title":"Circulation"},{"key":"50430_CR6","doi-asserted-by":"publisher","first-page":"j4","DOI":"10.1136\/bmj.j4","volume":"356","author":"S Bangalore","year":"2017","unstructured":"Bangalore, S. et al. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: Systematic review and meta-analysis of randomized trials. BMJ 356, j4. https:\/\/doi.org\/10.1136\/bmj.j4 (2017).","journal-title":"BMJ"},{"key":"50430_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti, J. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 41, 407\u2013477. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425 (2020).","journal-title":"Eur. Heart J."},{"key":"50430_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.11622\/smedj.2017044","volume":"58","author":"A Phrommintikul","year":"2017","unstructured":"Phrommintikul, A. et al. Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: A multicentre study. Singapore Med. J. 58, 535\u2013542. https:\/\/doi.org\/10.11622\/smedj.2017044 (2017).","journal-title":"Singapore Med. J."},{"key":"50430_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46, 399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786 (2011).","journal-title":"Multivar. Behav. Res."},{"key":"50430_CR10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/archinte.163.10.1155","volume":"163","author":"DS Jacoby","year":"2003","unstructured":"Jacoby, D. S. & Rader, D. J. Renin-angiotensin system and atherothrombotic disease: From genes to treatment. Arch. Intern. Med. 163, 1155\u20131164. https:\/\/doi.org\/10.1001\/archinte.163.10.1155 (2003).","journal-title":"Arch. Intern. Med."},{"key":"50430_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136702","author":"AV Poznyak","year":"2021","unstructured":"Poznyak, A. V. et al. Renin-angiotensin system in pathogenesis of atherosclerosis and treatment of CVD. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22136702 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"50430_CR12","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa042739","volume":"351","author":"E Braunwald","year":"2004","unstructured":"Braunwald, E. et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351, 2058\u20132068. https:\/\/doi.org\/10.1056\/NEJMoa042739 (2004).","journal-title":"N. Engl. J. Med."},{"key":"50430_CR13","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/s0002-9149(01)01461-8","volume":"87","author":"B Pitt","year":"2001","unstructured":"Pitt, B. et al. The QUinapril Ischemic Event Trial (QUIET): Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am. J. Cardiol. 87, 1058\u20131063. https:\/\/doi.org\/10.1016\/s0002-9149(01)01461-8 (2001).","journal-title":"Am. J. Cardiol."},{"key":"50430_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.106.685073","volume":"117","author":"JL Rouleau","year":"2008","unstructured":"Rouleau, J. L. et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 117, 24\u201331. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.685073 (2008).","journal-title":"Circulation"},{"key":"50430_CR15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/s0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox, K. M., Investigators, E. U. t. O. r. o. c. e. w. P. i. s. c. A. d. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362, 782\u2013788. https:\/\/doi.org\/10.1016\/s0140-6736(03)14286-9 (2003).","journal-title":"Lancet"},{"key":"50430_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"Heart Outcomes Prevention Evaluation Study, I. et al","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation Study, I. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145\u2013153. https:\/\/doi.org\/10.1056\/NEJM200001203420301 (2000).","journal-title":"N. Engl. J. Med."},{"key":"50430_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MCA.0000000000000609","volume":"29","author":"Y Choi","year":"2018","unstructured":"Choi, Y. et al. Renin-angiotensin system blockade reduces cardiovascular events in nonheart failure, stable patients with prior coronary intervention. Coron Artery Dis. 29, 451\u2013458. https:\/\/doi.org\/10.1097\/MCA.0000000000000609 (2018).","journal-title":"Coron Artery Dis."},{"key":"50430_CR18","doi-asserted-by":"publisher","first-page":"e011990","DOI":"10.1161\/JAHA.119.011990","volume":"8","author":"EH Choo","year":"2019","unstructured":"Choo, E. H. et al. Prognosis and predictors of mortality in patients suffering myocardial infarction with non-obstructive coronary arteries. J Am. Heart Assoc. 8, e011990. https:\/\/doi.org\/10.1161\/JAHA.119.011990 (2019).","journal-title":"J Am. Heart Assoc."},{"key":"50430_CR19","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/eurheartj\/ehz714","volume":"41","author":"E Bjorklund","year":"2020","unstructured":"Bjorklund, E. et al. Secondary prevention medications after coronary artery bypass grafting and long-term survival: A population-based longitudinal study from the SWEDEHEART registry. Eur. Heart J. 41, 1653\u20131661. https:\/\/doi.org\/10.1093\/eurheartj\/ehz714 (2020).","journal-title":"Eur. Heart J."},{"key":"50430_CR20","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","volume":"140","author":"SM Dunlay","year":"2019","unstructured":"Dunlay, S. M. et al. Type 2 diabetes mellitus and heart failure: A scientific statement from the american heart association and the heart failure society of America: This statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation 140, e294\u2013e324. https:\/\/doi.org\/10.1161\/CIR.0000000000000691 (2019).","journal-title":"Circulation"},{"key":"50430_CR21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"O Investigators","year":"2008","unstructured":"Investigators, O. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547\u20131559. https:\/\/doi.org\/10.1056\/NEJMoa0801317 (2008).","journal-title":"N. Engl. J. Med."},{"key":"50430_CR22","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","volume":"372","author":"Telmisartan Randomised AssessmeNt Study in, A. C. E. i. s. w. c. D. I. et al","year":"2008","unstructured":"Telmisartan Randomised AssessmeNt Study in, A. C. E. i. s. w. c. D. I. et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet 372, 1174\u20131183. https:\/\/doi.org\/10.1016\/S0140-6736(08)61242-8 (2008).","journal-title":"Lancet"},{"key":"50430_CR23","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt, D. L. et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304, 1350\u20131357. https:\/\/doi.org\/10.1001\/jama.2010.1322 (2010).","journal-title":"JAMA"},{"key":"50430_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3 (2019).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50430-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T14:12:05Z","timestamp":1703772725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50430-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["50430"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50430-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing  interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23066"}}